Arbutus Biopharma Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Arbutus Biopharma

ABUS 4.720

-2.4%

Oct 31 3:59 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: donpat	3/7/2014 11:29:09 AM
	Read Replies (1) of 42

Alnylam Pharmaceuticals acquires Sirna Therapeutics from Merck Mar 07, 2014 (Menafn - M2 EQUITYBITES via COMTEX) --RNAi therapeutics company Alnylam Pharmaceuticals (nasdaqgs:ALNY), based in the US, revealed on Thursday the completion of the acquisition of Sirna Therapeutics in a stock purchase agreement. Under the agreement, Alnylam Pharmaceuticals acquired Merck's wholly owned subsidiary Sirna Therapeutics following the expiration of the Hart-Scott-Rodino waiting period. In exchange for the Sirna common stock, Alnylam paid Merck USD25m in cash. The stock purchase agreement provides Alnylam all of Merck's rights, title, and interest in and to all of the outstanding shares of common stock of Sirna Therapeutics. Merck will receive 2,520,044 shares of Alnylam's common stock, valued at USD150m, representing 3% ownership position in Alnylam's outstanding common stock. Alnylam issued 85% of the shares at the closing and will issue the remainder of shares following the completion of certain technology transfer activities. Comments on this story may be sent to info@m2.com (C)1994-2014 M2 COMMUNICATIONS http://www.m2.com menafn.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next